A5032863911- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Retinoids in leukemia and cellular processes
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Cancer therapeutics and mechanisms
- Kruppel-like factors research
- Platelet Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Eosinophilic Disorders and Syndromes
- Microbial metabolism and enzyme function
- HER2/EGFR in Cancer Research
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Histone Deacetylase Inhibitors Research
- Aldose Reductase and Taurine
- Blood groups and transfusion
- Glioma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Vascular Tumors and Angiosarcomas
- Cancer Research and Treatments
Emory University
2020-2025
University of Alabama at Birmingham
2017-2024
Stanford Cancer Institute
2018
The University of Texas MD Anderson Cancer Center
2018
Sidney Kimmel Comprehensive Cancer Center
2018
Barnes-Jewish Hospital
2018
Smilow Cancer Hospital
2018
Yale Cancer Center
2018
Duke Medical Center
2018
Cancer Institute (WIA)
2018
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV ET characterized by significant thrombohemorrhagic complications high risk transformation to MF acute myeloid leukemia. The diagnosis management has evolved since identification mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss recommendations outlined Guidelines for...
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation abnormal mast cells and their accumulation in skin and/or various extracutaneous organs. Systemic mastocytosis most common form diagnosed adults, characterized by cell infiltration one or more organs (with without involvement). The identification KIT D816V mutation emergence novel targeted therapies have significantly improved diagnosis treatment systemic mastocytosis. However, certain aspects clinical...
Lysyl oxidase (LOX), a matrix cross-linking protein, is known to be selectively expressed and enhance fibrotic phenotype. A recent study of ours showed that LOX oxidizes the PDGF receptor-β (PDGFR-β), leading amplified downstream signaling. Here, we examined expression functions in megakaryocytes (MKs), platelet precursors. Cells committed MK lineage undergo mitotic proliferation yield diploid cells, followed by endomitosis acquisition polyploidy. Intriguingly, detected diploid-tetraploid...
Myelofibrosis (MF) is an essential element of primary myelofibrosis, whereas secondary MF may develop in the advanced stages other myeloid neoplasms, especially polycythemia vera and thrombocythemia. Over last two decades, advances molecular diagnostic techniques, particularly integration next-generation sequencing clinical laboratories, have revolutionized diagnosis, classification, decision making myelofibrosis. Driver mutations involving JAK2, CALR, MPL induce hyperactivity JAK-STAT...
Megakaryocytes are platelet precursor cells that undergo endomitosis. During this process, repeated rounds of DNA synthesis characterized by lack late anaphase and cytokinesis. Physiologically, the majority polyploid megakaryocytes in bone marrow cell cycle arrested. As previously reported, cyclin E is essential for megakaryocyte polyploidy; however, it has remained unclear whether up-regulated an inducer polyploidy vivo. We found upon stimulation primary thrombopoietin. Transgenic mice...
Abstract To investigate aldo–keto reductase 1C3 (AKR1C3) expression in T and B acute lymphoblastic leukemia/lymphoma (ALL) patients. Three commercial antibodies were evaluated for AKR1C3 immunohistochemistry (IHC) staining performance: Polyclonal Thermofisher scientific (Clone#PA523667), rabbit monoclonal Abcam [EPR16726] (ab209899) Sigma/Millipore anti-AKR1C3 antibody, mouse monoclonal, clone NP6.G6.A6, purified from hybridoma cell culture. Initial optimization was performed on line...
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, introduction molecular assays has improved our ability to diagnose MDS. The role Measurable (minimal) Residual Disease (MRD) in MDS is evolving, flow cytometry techniques used several studies. this review, we will highlight evolving concept MRD MDS, outline various utilized, provide an overview studies reporting correlation with outcomes.
Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen (SYK) and FMS-like 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability, efficacy of mivavotinib in patients refractory and/or relapsed (R/R) acute myeloid leukemia (AML). Both daily (QD) twice (BID) dosing regimens were evaluated. A total 43 enrolled, there 5 complete responses (4 incomplete count recovery). In QD regimen, maximum tolerated dose (MTD) was...